



# RNA binding protein HuD contributes to $\beta$ -cell dysfunction by impairing mitochondria dynamics

Youlim Hong<sup>1</sup> · Hyosun Tak<sup>1</sup> · Chongtae Kim<sup>1,2</sup> · Hoin Kang<sup>1</sup> · Eunbyul Ji<sup>1</sup> · Sojin Ahn<sup>1</sup> · Myeongwoo Jung<sup>1</sup> · Hong Lim Kim<sup>3</sup> · Jeong-Hwa Lee<sup>1,4</sup> · Wook Kim<sup>5</sup> · Eun Kyung Lee<sup>1,4</sup>

Received: 1 April 2019 / Revised: 16 October 2019 / Accepted: 17 October 2019 / Published online: 28 October 2019  
© The Author(s), under exclusive licence to ADMC Associazione Differenziamento e Morte Cellulare 2019

## Abstract

Imbalanced mitochondrial dynamics in pancreatic  $\beta$ -cells contributes to  $\beta$ -cell dysfunction in diabetes; however, the molecular mechanisms underlying mitochondrial dynamics in the pathology of diabetes are not fully elucidated. We previously reported the reduction of RNA binding protein HuD in pancreatic  $\beta$ -cells of diabetes. Herein, we demonstrate that HuD plays a novel role in the regulation of mitochondrial dynamics by promoting mitochondrial fusion. We show enhanced mitochondrial fragmentation in the pancreas of *db/db* mice and HuD KO mice. Downregulation of HuD increases the number of cells with fragmented mitochondria and reduces the mitochondrial activity determined by mitochondrial membrane potential and ATP production in mouse insulinoma  $\beta$ TC6 cells. HuD binds to 3'-untranslated region of *mitofusin 2* (*Mfn2*) mRNA and positively regulates its expression. Ectopic expression of *Mfn2* in  $\beta$ TC6 cells stably expressing short hairpin RNA against HuD (shHuD) restores HuD-mediated mitochondrial dysfunction. Taken together, our results suggest that HuD regulates mitochondrial dynamics by regulating *Mfn2* level and its reduced expression leads to mitochondrial dysfunction in pancreatic  $\beta$ -cells.

## Introduction

Mitochondria play crucial roles in cellular energy homeostasis and apoptosis by regulating cellular energy

production, reactive oxygen species generation, and signal transduction [1–3]. Mitochondria continuously change their morphology through fusion and fission in response to the physiological demands of cells, which is critical to the organelle's function [4–6]. Abnormal regulation of mitochondrial dynamics has been implicated in the pathogenesis of several human diseases, in particular, metabolic disorders [5, 7–9]. Enhanced fission and reduced fusion were previously reported in obesity and diabetes [10, 11]. The differential expression of mitochondrial dynamics regulating proteins, such as dynamin related protein 1 (Drp1), optic atrophy protein 1 (Opa1), mitofusin 1/2 (*Mfn1/2*), and mitochondria fission factor (*Mff*), is responsible for the imbalance between fusion and fission, and contributes to mitochondrial dysfunction [12, 13]. Emerging evidence suggests that the tight regulation of mitochondrial dynamics plays an important role in the maintenance of mitochondrial homeostasis and in the pathogenesis of diseases; however, the underlying mechanisms need to be further elucidated.

Mitofusin 2 (*Mfn2*), a 757 aa protein containing several well-conserved domains, mediates oligomerization of two adjacent mitochondria via heptad-repeat domains, and regulates mitochondrial distribution, shape, and quality control [14]. *Mfn2* has been shown to play a key role in metabolism: *Mfn2* depletion leads to reduced mitochondrial membrane potential,

---

Edited by D. Rubinsztein

**Supplementary information** The online version of this article (<https://doi.org/10.1038/s41418-019-0447-x>) contains supplementary material, which is available to authorized users.

✉ Eun Kyung Lee  
leek@catholic.ac.kr

- <sup>1</sup> Department of Biochemistry, The Catholic University of Korea College of Medicine, Seoul 06591, South Korea
- <sup>2</sup> Catholic Institute for Visual Science, The Catholic University of Korea College of Medicine, Seoul 06591, South Korea
- <sup>3</sup> Integrative Research Support Center, Laboratory of Electron Microscope, The Catholic University of Korea College of Medicine, Seoul 06591, South Korea
- <sup>4</sup> Institute of Aging and Metabolic Diseases, The Catholic University of Korea College of Medicine, Seoul 06591, South Korea
- <sup>5</sup> Department of Molecular Science and Technology, Ajou University, Suwon 16499, South Korea

cellular oxygen consumption, and mitochondrial proton leak, whereas Mfn2 overexpression promotes oxidative phosphorylation, glucose oxidation, and insulin sensitivity [12, 15–19]. Mfn2 also mediates the interaction between mitochondria and endoplasmic reticulum (ER) and regulates ER stress in response to metabolic stress [20]. Downregulation of Mfn2 expression has been reported in obesity and diabetes, and it suggests the implication of Mfn2 in the pathophysiology of metabolic diseases [12, 14, 15].

Mfn2 expression is regulated at the levels of transcription, posttranscription, and posttranslation. Estrogen-related receptor- $\alpha$ , peroxisome proliferator-activated receptor gamma coactivator 1-beta, and lysocardiolipin acyltransferase 1 regulate *Mfn2* transcription [21–23]. microRNAs (miRNAs) including miR-17, -31, -106b, -125a, -195, -214, -497, and -761, suppress, while a long noncoding RNA *Plscr4* increases, Mfn2 expression [24–36]. Phosphorylation-dependent ubiquitination by JNK and Wuwei1 also regulates the level of Mfn2 [37]. In addition, Mfn2 activity is affected by protein–protein interactions such as the Smad2-RIN complex [38]. Although several studies have identified the factors regulating the expression or activity of Mfn2, the underlying mechanisms in physiological or pathological conditions need to be further determined.

HuD, one of members of human antigen Hu/ELAVL family, plays an essential role in posttranscriptional regulation of gene expression by controlling mRNA turnover or translation in certain types of cells including neurons and pancreatic  $\beta$ -cells [39–45]. Herein, we identified HuD as a novel factor regulating mitochondrial dynamics and function by promoting Mfn2 expression. Mitochondrial fragmentation is enhanced in pancreatic islets of diabetic *db/db* mice and HuD knockout (KO) mice. Mitochondrial morphology and activity is regulated in an HuD-dependent manner in the mouse pancreatic  $\beta$ -cell line,  $\beta$ TC6. HuD increases Mfn2 expression by associating with 3'-untranslated region (3'UTR) of *Mfn2* mRNA, thereby promoting mitochondrial fusion. Ectopic expression of Mfn2 restores HuD-mediated mitochondrial dysfunction. Our data reveal that HuD plays an essential role in the regulation of mitochondrial homeostasis and its reduction may contribute to impaired mitochondrial function resulting  $\beta$ -cell dysfunction.

## Results

### Mitochondrial fragmentation is enhanced in diabetic islets


Mitochondria dysfunction has been reported in a diverse diabetes models and abnormal mitochondrial morphology is known to be associated with mitochondrial dysfunction in the pathogenesis of diabetes [11, 46–48]. We investigated the mitochondrial morphology in the pancreas of leptin receptor-

deficient mice (*db/db* mice), one of the diabetes models, compared with normal C57BL/6J mice using an electron microscope. The results show that mitochondria in pancreatic islets of *db/db* mice were smaller than those of the control mice (Fig. 1a). Our previous study demonstrated that lower HuD expression in pancreatic islets contributed to  $\beta$ -cell dysfunction [44]. To elucidate the relationship between HuD and mitochondrial dynamics, we also analyzed the mitochondrial morphology of pancreatic islets in HuD KO mice. We found that mitochondria in pancreatic islets of KO mice were rounded and smaller than those derived from wildtype mice (Fig. 1b). These observations suggest that mitochondrial fragmentation is enhanced in diabetic islets and HuD plays a role in the regulation of mitochondrial dynamics.

### HuD functions as an essential regulator in the maintenance of mitochondrial morphology and function

Our previous studies shows HuD plays pivotal roles in pancreatic  $\beta$ -cells and its expression is reduced in the pancreas of *db/db* mice [42–44]. Figure 1b shows abnormal mitochondrial morphology in the pancreatic islets of HuD KO mice. To determine whether HuD has a potential to regulate mitochondrial dynamics, we analyzed mitochondrial morphology in  $\beta$ TC6 cells transfected with HuD siRNA or in a stable cell line expressing a short hairpin RNA against HuD (shHuD) [44] by staining with MitoTracker<sup>®</sup> or electron microscopy. Downregulation of HuD resulted in fragmentation of mitochondria in  $\beta$ TC6 cells as shown in Fig. 2a, c. To test the effect of HuD overexpression on mitochondrial dynamics, we transduced  $\beta$ TC6 cells with a retrovirus containing HA-tagged HuD (pHuD) and analyzed mitochondrial morphology. HuD overexpression increased mitochondrial fusion in  $\beta$ TC6 cells (Fig. 2b, d). These results suggest that HuD has a role in the regulation of mitochondrial dynamics by promoting mitochondrial elongation.

It has been suggested that dynamic changes in mitochondrial morphology are essential for their functions, including cellular respiration and ATP generation. An imbalance of mitochondrial dynamics is usually linked to mitochondrial dysfunction and leads to pathogenesis of several diseases such as neurodegenerative diseases and diabetes [2–4, 46]. To address whether HuD affects to the function of mitochondria, we assessed mitochondrial activity by measuring mitochondrial membrane potential after HuD overexpression or knockdown in pancreatic  $\beta$ -cells. HuD overexpression increased, while HuD knockdown decreased mitochondrial membrane potential based on JC-1 staining (Fig. 3a). In addition, the level of mitochondrial ATP was positively regulated by HuD (Fig. 3b). These observations indicate that HuD expression is linked to mitochondrial function. Consistent with these results, a reduction in mitochondrial activity



**Fig. 1** Mitochondrial morphology in the pancreas of diabetic mice. Mitochondrial morphology was analyzed in the pancreas of normal *C57BL/6J* and diabetic (*Lepr<sup>db/db</sup>*) mice (**a**) and the pancreas of HuD knockout mice (**b**) using a transmission electron microscope (TEM).


Bar, 0.2  $\mu$ m. Fifty mitochondria from each group were counted according to their relative length. Images are representative and the values indicate the mean  $\pm$  SEM obtained from three independent analyses. \* $p < 0.05$ ; \*\* $p < 0.01$ ; \*\*\* $p < 0.001$

was confirmed in shHuD cells, which indicated that the loss of HuD impaired mitochondrial function (Fig. 3c). In addition, we investigated the impact of HuD on cellular respiration by assessing oxygen consumption rate (OCR) between shHuD cells and shCtrl cells using the Seahorse FX24 Extracellular Flux Analyzer. Basal OCR and maximal OCR assessed by FCCP treatment in shHuD cells were lower than those in shCtrl cell (Fig. 3d), indicating that HuD down-regulation impaired basal and maximal rates of mitochondrial respiration. However, no significant change on electron flow through the ETC or nonmitochondrial respiration of both cells was observed. Taken together, these results suggest that HuD plays an essential role in the regulation of mitochondrial morphology and function in pancreatic  $\beta$ -cells.

### HuD binds to *Mfn2* mRNA and regulates its expression

To determine the target mRNAs of HuD involved in the regulation of mitochondrial morphology and function, HuD-associated mRNAs were isolated and identified by

HuD-RIP assay followed by microarray. The mRNAs enriched more than fivefold in HuD IP shown in Supplementary Table 1 were further screened by gene ontology-based analysis of genes related to mitochondrial function. This survey identified seven mRNAs including *apoptosis inducing factor mitochondria associated 2 (AIFM2)*, *diablo IAP-binding mitochondrial protein (DIABLO)*, *frataxin (Fxn)*, *heat shock 70 KDa Protein 9 (HSPA9, mortalin)*, *mitochondrial tumor suppressor gene 1 (MTUS1)*, *Mfn2*, and *mitochondrial transcription factor A (TFAM)* as putative targets of HuD (Fig. 4a). The association between HuD and these mRNAs was validated by RIP analysis followed by RT-qPCR, and the results showed that *Mfn2* mRNA was significantly enriched in HuD-IP compared with normal IgG (Fig. 4b). It suggests that HuD binds to *Mfn2* mRNA. HuD is known to regulate mRNA turnover and translation by binding to the 3'UTR of target mRNAs [42, 45, 49, 50]. Therefore, we further assessed the interaction between HuD and *Mfn2* mRNA via in vitro pull-down assay using biotin-labeled transcripts corresponding to the 5'UTR (*Mfn2* 5U) and 3'UTR of *Mfn2* mRNA (*Mfn2* 3U-1 and 3U-2) and



**Fig. 2** Regulation of mitochondrial morphology by HuD. **a, b** HuD knockdown  $\beta$ TC6 cells using either siRNA (left) or small hairpin RNA (right) (**a**) and HuD overexpressing  $\beta$ TC6 cells using a retrovirus carrying HA-HuD (pHuD) (**b**) were incubated with MitoTracker<sup>®</sup> and the mitochondrial morphology was analyzed using a fluorescence microscope. Bar, 4  $\mu$ m. The number of mitochondria was assessed by counting

at least 300 cells from three independent experiments. Western blot analysis shows relative level of HuD and  $\beta$ -actin. **c, d** Mitochondrial morphology of  $\beta$ TC6-shHuD cells and  $\beta$ TC6 cells after HuD overexpression (pHuD) was analyzed with a TEM. Bar, 0.5  $\mu$ m. Images are representative and the values indicate the mean  $\pm$  SEM from three independent analyses. \* $p < 0.05$ ; \*\* $p < 0.01$ ; \*\*\* $p < 0.001$

streptavidin beads. As shown in Fig. 4c, HuD bound to both transcripts of *Mfn2* 3U-1 and 3U-2. These results indicate that *Mfn2* mRNA is the target of HuD.


HuD is downregulated in the pancreas of diabetic models [44]. We demonstrate that it binds to *Mfn2* mRNA (Fig. 4). To determine whether HuD affects *Mfn2* expression, we assessed *Mfn2* level using RT-qPCR and western blot analysis after HuD downregulation. Knockdown of HuD using HuD siRNA in  $\beta$ TC6 cells decreased both *Mfn2* mRNA and protein level (Fig. 5a), which was further confirmed in shHuD cells (Fig. 5b). In addition, we investigated the HuD-mediated regulation of *Mfn2* expression by assessing the EGFP reporter level. Based on the interaction between HuD and the 3'UTR of *Mfn2*

mRNA (Fig. 4c), we generated EGFP reporters containing the 3'UTR of *Mfn2* mRNA (EGFP-*Mfn2*-3U1 and 3U2) (Fig. 5c) and analyzed EGFP expression after transfection of HuD siRNA. HuD knockdown decreased the EGFP expressions of both *Mfn2*-3U1 and 3U2 reporters (Fig. 5d), indicating that HuD downregulation decreases *Mfn2* expression. Taken together, these results suggest that HuD regulates *Mfn2* expression by associating its 3'UTR.

### The HuD/*Mfn2* axis plays an essential role in the regulation of mitochondrial morphology

*Mfn2* regulates mitochondrial function by controlling mitochondrial elongation [16, 51, 52]. Our observations


**Fig. 3** Regulation of mitochondrial activity by HuD. **a, b** After transfection of  $\beta$ TC6 cells with HuD siRNA or pHuD with appropriate controls, mitochondrial membrane potential (**a**) and mitochondrial ATP levels (**b**) were analyzed. Cells were stained with tetraethyl benzimidazoly carbocyanine iodide (JC-1) and the fluorescence was measured at 530 nm (excitation)/590 nm (emission). Cells pretreated with galactose-containing media were incubated with the ATP detection reagent and the luminescence was measured using a microplate reader. **c** Mitochondrial membrane potential and ATP level were determined in  $\beta$ TC6-shHuD and  $\beta$ TC6-shCtrl cells. **d** Mitochondrial respiration in  $\beta$ TC6-shCtrl and  $\beta$ TC6-shHuD cells was determined by assessing the oxygen consumption rate. Cells were sequentially incubated with oligomycin, FCCP, rotenone, and antimycin A and OCR was measured using the Seahorse FX24 Extracellular Flux Analyzer. Data represent the mean  $\pm$  SEM derived from three independent experiments. \* $p < 0.05$ ; \*\* $p < 0.01$ ; \*\*\* $p < 0.001$



suggest that HuD acts as a novel factor regulating Mfn2 expression at the posttranscriptional level (Figs. 4 and 5). To evaluate whether the HuD/Mfn2 axis play a role in the regulation of mitochondrial morphology and function, we performed a complementation experiment by overexpressing myc-tagged Mfn2 in shHuD cells (Fig. 6a). As shown in Fig. 6b, ectopic expression of Mfn2 increased the portion of cells with elongated mitochondria in shHuD cells (Fig. 6b). In addition, mitochondrial membrane potential and mitochondrial ATP levels were moderately restored by Mfn2 overexpression (Fig. 6c). These results suggest that the HuD/Mfn2 axis regulates mitochondrial morphology and function, and aberrant expression of HuD in pancreatic  $\beta$ -cells results in mitochondrial dysfunction in diabetes.

## Discussion

Tight regulation of mitochondrial structure and activity is critical for cellular homeostasis. Mitochondrial dysfunction is characterized by a reduction in ATP generation, mitochondrial membrane potential, and mitochondrial numbers, and is implicated in the pathology of several human diseases, such as diabetes, neurodegenerative diseases, and cancers. Dynamic regulation of mitochondrial morphology is essential for the normal function of mitochondria and is mediated by several key regulatory proteins including Drp1, Opa1, Fis1, Mff, and Mfn1/2. Herein, we demonstrate that the RNA binding protein HuD plays a novel role in mitochondrial dynamics via posttranscriptional regulation of Mfn2, resulting in mitochondrial dysfunction in pancreatic  $\beta$ -cells. We showed that HuD binds to 3'UTR of *Mfn2*



**Fig. 4** Identification of target mRNAs of HuD. **a** Putative targets of HuD identified by both HuD-RIP analysis and GO term analysis (mitochondrial function). **b** The interaction between HuD and target mRNAs was confirmed by RIP-qPCR using anti-HuD and control IgG antibodies. *Gapdh* mRNA was used for normalization. **c** *Left*: A schematic of mouse *Mfn2* mRNA (NM\_001285920). The 5'UTR (5U) and 3'UTR of *Mfn2* mRNAs (3U-1 and 3U-2) were transcribed in vitro

and biotinylated for use in biotin pull-down analysis. *Right*: The biotinylated transcripts obtained from *Mfn2* mRNA were incubated with  $\beta$ TC6 cell lysates. The interaction between the transcripts and HuD was shown by western blot. Biotinylated *Gapdh* 3'UTR transcript was used as a negative control. Data represent the mean  $\pm$  SEM derived from three independent experiments. \*\* $p < 0.01$

mRNA and promotes *Mfn2* expression, thereby enhancing mitochondrial elongation. We also demonstrated mitochondrial fragmentation in pancreatic  $\beta$ -cells of diabetic mice, with a lower expression of HuD. Our data reveal that HuD regulates mitochondrial dynamics via posttranscriptional control of *Mfn2* expression.


It is still disputed whether mitochondrial dysfunction is a cause or a consequence of diabetes; however, several studies suggest that abnormal mitochondrial function in pancreatic  $\beta$ -cells plays a decisive role in metabolic dysregulation and hyperglycemia [47, 48, 53, 54]. Alteration of mitochondrial morphology in pancreatic  $\beta$ -cells, in particular, fragmentation of mitochondria has been reported in diabetic pancreas [11, 46, 55–57]. Herein, we also report enhanced mitochondrial fission, matrix swelling, and disruption of cristae in pancreatic  $\beta$ -cells of diabetic mice (Fig. 1a). A few key proteins regulating mitochondrial fission and fusion, including Fis1 and Opa1 have been linked to  $\beta$ -cell dysfunction by affecting mitochondrial dynamics [9, 58, 59]. We propose that HuD-mediated *Mfn2* regulation also mediates  $\beta$ -cell dysfunction. Because of the complex and possibly synergistic processes involved, elucidation of the molecular relationship between  $\beta$ -cell dysfunction and mitochondrial dynamics is needed.

Our previous report shows that the HuD level is down-regulated in the pancreas of diabetic mice [44]. HuD is an RNA binding protein belonging to Hu antigen family and is expressed in certain types of tissues including neurons and pancreatic  $\beta$ -cells [42]. Various target mRNAs of HuD have

been identified, while the regulatory mechanism is poorly understood. Posttranslational modifications including phosphorylation by protein kinase C and methylation by coactivator-associated arginine methyltransferase 1 regulate HuD activity [60, 61]. In addition, miRNA-375, one of the enriched miRNAs in the pancreas, acts as a negative regulator of HuD [41]. The miR-375 KO mice show impaired glucose homeostasis by regulating  $\beta$ -cell mass [62]. Therefore, it is worth exploring whether mitochondrial dysfunction occurred in miR-375 KO mice. Further studies exploring the regulation of HuD expression in diabetes may provide the molecular link underlying HuD-mediated  $\beta$ -cell dysfunction.

RIP analysis and in vitro pull-down assay using biotin-labeled transcripts reveal the interaction between HuD and 3'UTR of *Mfn2* mRNA (Fig. 4). Tracing the expression of reporters containing 3'UTRs of *Mfn2* mRNA may shed additional light on the interactions (Fig. 5d). Both 3U1 and 3U2 regions of 3'UTRs of *Mfn2* mRNA are regulated by HuD. The binding of 3U1 region to HuD is relatively strong, while that of 3U2 is moderate, but consistent. Although we could not determine the exact HuD-binding motifs on 3'UTRs of *Mfn2* mRNA, 3U1 appears to be subject to dominant regulation by HuD. Crosslinking immunoprecipitation and RNA sequencing analysis in pancreatic  $\beta$ -cells may provide additional information about the sequence responsible for HuD binding.

In conclusion, we propose that HuD is a novel regulatory protein affecting mitochondrial dynamics by enhancing



**Fig. 5** Regulation of *Mfn2* expression by HuD. *Mfn2* mRNA and protein levels were analyzed in  $\beta$ TC6 cells transfected with siHuD (**a**) or  $\beta$ TC6-shHuD (**b**) cells by RT-qPCR and western blot analysis, respectively. **c** Schematic representation of EGFP reporter constructs containing *Mfn2* mRNA 3'UTRs (pEGFP-Mfn2-3U1 and -3U2).

**d** Following sequential transfection with a reporter plasmid after HuD knockdown in  $\beta$ TC6 cells, the relative EGFP expression was determined by measuring the fluorescence of EGFP and western blot analysis. Data represent the mean  $\pm$  SEM from three independent experiments. \*\* $p < 0.01$ ; \*\*\* $p < 0.001$

*Mfn2* expression. Our results suggest that downregulation of HuD in diabetes may contribute to impaired mitochondrial shape and function. Further studies investigating the differential expression of HuD in pancreatic  $\beta$ -cells and the underlying molecular mechanisms may provide additional insight into the role of HuD-mediated mitochondrial dynamics in the pathogenesis of diabetes.

## Materials and methods

### Cell culture, transfection of plasmids, and small interfering RNAs

Mouse pancreatic  $\beta$ -cell line,  $\beta$ TC6 cells were cultured in Dulbecco's Modified Eagle's Medium (Capricorn scientific, Ebsdorfergrund, Germany) supplemented with 10% fetal bovine serum and 1% antibiotics.  $\beta$ TC6 cell clones stably expressing shHuD plasmid ( $\beta$ TC6-shHuD) was established and maintained with puromycin (Invitrogen, Carlsbad, CA, USA). HuD overexpression plasmid (pHuD) was prepared by cloning CDS of mouse *HuD* mRNA into a retroviral vector pPGS-HA and viral particles were prepared using HEK293 cells. Enhanced green fluorescent protein (EGFP) reporters were cloned by inserting the 3'UTR of *Mfn2* mRNA (2757–4559, 1803 nt) into pEGFP-C1 vector (BD Bioscience, Franklin lake, NJ, USA). Plasmids (pEGFP, pHuD, pMfn2 (Addgene, #23213)) and small interfering RNAs (siRNAs;


control siRNA (siCtrl) and HuD siRNA (siHuD)); Genolution Pharmaceuticals, Seoul, Korea) were transiently transfected using Lipofectamine<sup>TM</sup> 2000 (Invitrogen).

### Western blot analysis

Whole cell lysates were prepared using RIPA buffer (10 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% NP-40, 1 mM EDTA, and 0.1% SDS) containing a 1 $\times$  protease inhibitor cocktail (Roche, Basel, Switzerland), separated by SDS polyacrylamide gel electrophoresis, and transferred onto polyvinylidene difluoride membranes (Millipore, Billerica, MA, USA). The membranes were incubated with primary antibodies against HuD (Santa Cruz Biotechnology, Dallas, TX, USA), *Mfn2* (Abcam, Cambridge, USA), EGFP (Santa Cruz Biotechnology), HA (Biolegend, San Diego, CA, USA), and  $\beta$ -actin (Abcam), and further incubated with the appropriate secondary antibodies conjugated with horseradish peroxidase (Santa Cruz Biotechnology). Protein bands were detected using enhanced chemiluminescence (Bio-Rad, Hercules, CA, USA).

### RNA analysis

Total RNA was isolated from whole cells using RNAiso plus Reagent (Takara Bio Inc, Shiga, Japan). After reverse transcription (RT) using random hexamers and reverse transcriptase (Toyobo, Osaka, Japan), the mRNA levels



**Fig. 6** Regulation of mitochondrial dynamics along the HuD/Mfn2 axis.  $\beta$ TC6-shCtrl and  $\beta$ TC6-shHuD cells were transfected with pMfn2 and pCtrl. **a** Mfn2 and HuD protein levels were analyzed by western blot analysis. **b** After transfection with pMfn2, cells were incubated with MitoTracker<sup>®</sup> and mitochondrial morphology was analyzed using

a fluorescence microscope. Bar, 5  $\mu$ m. **c** After transfection with pMfn2, mitochondrial membrane potential and ATP level were determined by JC-1 staining and mitochondrial ToxGlo<sup>™</sup> assay. Data represent the mean  $\pm$  SEM derived from three independent experiments. \* $p < 0.05$ ; \*\*\* $p < 0.001$

were quantified by real time quantitative PCR analysis using SensiFAST<sup>™</sup> SYBR<sup>®</sup> Hi-ROX Kit (Bioline, London, UK) and gene-specific primer sets (Supplementary Table 2). RT-qPCR analysis was performed using StepOnePlus<sup>™</sup> (Applied Biosystems, Foster City, CA, USA).

### Ribonucleoprotein complex-immunoprecipitation and qPCR (RIP-qPCR) analysis

RNP complexes were immunoprecipitated using Protein A bead (Invitrogen) coated with anti-HuD or control IgG antibodies (Santa Cruz Biotechnology) at 4 °C overnight [43]. The immunoprecipitated RNP complexes were incubated with DNase I and proteinase K. RNAs were isolated

from the complex and further analyzed by RT-qPCR using the primers listed (Supplementary Table 2).

### Biotin pull down assay

To synthesize biotinylated transcripts, PCR fragments were prepared using forward primers, including T7 RNA polymerase promoter sequence (T7, 5'-CCAAGCTTCTAATACGACTCACTATAGG-GAGA-3'). Primers used to prepare biotinylated transcripts *Mfn2* mRNA (NM\_001285920.1) are listed in Supplementary Table 2. After purification of the PCR products, biotinylated transcripts were synthesized using the MaxiScript T7 kit (Ambion, Waltham, MA, USA) and biotin-CTP (Enzo Life Sciences, Farmingdale, NY, USA).

Whole-cell lysates (300  $\mu$ g per sample) were incubated with 1  $\mu$ g of purified biotinylated transcripts for 30 min at room temperature, and the complexes were isolated using streptavidin-coupled Dynabeads (Invitrogen). Proteins were isolated from the complex and further studied by western blot analysis [43].

### Morphological analysis of mitochondria

$\beta$ TC6 cells were incubated with 100 nM Mitotracker Red CMXRos (Invitrogen) for 30 min at 37 °C. Mitochondria morphology of either  $\beta$ TC6 cells treated with Mitotracker or mt-YFP expressing  $\beta$ TC6 cells was observed using a fluorescence microscope. The fluorescent images were acquired using an Axiovertcam mRM camera attached to an Axiovert 200M (Carl Zeiss, Jena, Germany).

For electron microscopy, tissues or cells were fixed with 1% glutaraldehyde and embedded using Epon 812. Ultrathin sections were observed with a transmission electron microscope JEM 1010 (JEOL, Tokyo, Japan).

### Measurement of the mitochondrial membrane potential and mitochondrial ATP level

Mitochondrial membrane potential was measured using the tetraethyl benzimidazolyl carbocyanine iodide (JC-1) staining solution (Abcam) according to the manufacturer's protocol. Cells were incubated with the reagent for 15 min and the fluorescence was measured at 535 nm (excitation)/590 nm (emission) using the Synergy™ H1 multimode microplate reader (BioTek, VT, USA). Mitochondrial ATP level was also measured using the Mitochondrial Toxglo™ assay kit (Promega, Madison, WI, USA). After incubating cells with galactose-containing media, cells were incubated with the ATP detection reagent at 37 °C for 90 min and the luminescence was assessed with the Synergy™ H1 hybrid microplate reader (BioTek, VT, USA).

### Analysis of oxygen consumption rate

OCR between  $\beta$ TC6-shCtrl and  $\beta$ TC6-shHuD cells was determined using the Seahorse FX24 Extracellular Flux Analyzer (Seahorse Bioscience, North Billerica, MA, USA) with an XF Cell Mito Stress Test Kit (Seahorse Bioscience) according to the manufacturer's instruction. An ATP synthase blocker, oligomycin (3  $\mu$ M) and the mitochondrial uncoupler, FCCP (carbonyl cyanide 4-[trifluoromethoxy] phenylhydrazone, 1  $\mu$ M) were used to measure the proton leakage and the maximal OCR, respectively. An inhibitor of complex I, rotenone (1  $\mu$ M) and a complex III blocker, antimycin A (1  $\mu$ M) were used to determine the non-mitochondrial respiration. The results were analyzed using a Seahorse XF Prep Station [63].

### Statistical analysis

Data were expressed as mean  $\pm$  SEM of three independent experiments. The statistical significances of the data were analyzed by Student's *t* test; \* $p$  < 0.05; \*\* $p$  < 0.01; \*\*\* $p$  < 0.001.

**Acknowledgements** This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (2017R1A2B2009381, 2017R1A2B2005508, and 2019M3E5D5066526).

### Compliance with ethical standards

**Conflict of interest** The authors declare that they have no conflict of interest.

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

### References

- McBride HM, Neuspiel M, Wasiak S. Mitochondria: more than just a powerhouse. *Curr Biol*. 2006;16:R551–60.
- Johannsen DL, Ravussin E. The role of mitochondria in health and disease. *Curr Opin Pharmacol*. 2009;9:780–6.
- Duchen MR, Szabadkai G. Roles of mitochondria in human disease. *Essays Biochem*. 2010;47:115–37.
- Youle RJ, van der Bliek AM. Mitochondrial fission, fusion, and stress. *Science*. 2012;337:1062–5.
- Roy M, Reddy PH, Iijima M, Sesaki H. Mitochondrial division and fusion in metabolism. *Curr Opin Cell Biol*. 2015;33:111–8.
- Tilokani L, Nagashima S, Paupe V, Prudent J. Mitochondrial dynamics: overview of molecular mechanisms. *Essays Biochem*. 2018;62:341–60.
- Putti R, Sica R, Migliaccio V, Lionetti L. Diet impact on mitochondrial bioenergetics and dynamics. *Front Physiol*. 2015;6:109.
- Montgomery MK, Turner N. Mitochondrial dysfunction and insulin resistance: an update. *Endocr Connect*. 2015;4:R1–R15.
- Baltrusch S. Mitochondrial network regulation and its potential interference with inflammatory signals in pancreatic beta cells. *Diabetologia*. 2016;59:683–7.
- Holmstrom MH, Iglesias-Gutierrez E, Zierath JR, Garcia-Roves PM. Tissue-specific control of mitochondrial respiration in obesity-related insulin resistance and diabetes. *Am J Physiol Endocrinol Metab*. 2012;302:E731–9.
- Anello M, Lupi R, Spampinato D, Piro S, Masini M, Boggi U, et al. Functional and morphological alterations of mitochondria in pancreatic beta cells from type 2 diabetic patients. *Diabetologia*. 2005;48:282–9.
- Bach D, Pich S, Soriano FX, Vega N, Baumgartner B, Oriola J, et al. Mitofusin-2 determines mitochondrial network architecture and mitochondrial metabolism. A novel regulatory mechanism altered in obesity. *J Biol Chem*. 2003;278:17190–7.
- Jheng HF, Tsai PJ, Guo SM, Kuo LH, Chang CS, Su IJ, et al. Mitochondrial fission contributes to mitochondrial dysfunction and insulin resistance in skeletal muscle. *Mol Cell Biol*. 2012;32:309–19.
- Schrepfer E, Scorrano L. Mitofusins, from mitochondria to metabolism. *Mol Cell*. 2016;61:683–94.
- Bach D, Naon D, Pich S, Soriano FX, Vega N, Rieusset J, et al. Expression of Mfn2, the Charcot-Marie-Tooth neuropathy type

- 2A gene, in human skeletal muscle: effects of type 2 diabetes, obesity, weight loss, and the regulatory role of tumor necrosis factor alpha and interleukin-6. *Diabetes*. 2005;54:2685–93.
16. Chen H, Chomyn A, Chan DC. Disruption of fusion results in mitochondrial heterogeneity and dysfunction. *J Biol Chem*. 2005;280:26185–92.
  17. Pich S, Bach D, Briones P, Liesa M, Camps M, Testar X, et al. The Charcot-Marie-Tooth type 2A gene product, Mfn2, up-regulates fuel oxidation through expression of OXPHOS system. *Hum Mol Genet*. 2005;14:1405–15.
  18. Sebastian D, Hernandez-Alvarez MI, Segales J, Soriano E, Munoz JP, Sala D, et al. Mitofusin 2 (Mfn2) links mitochondrial and endoplasmic reticulum function with insulin signaling and is essential for normal glucose homeostasis. *Proc Natl Acad Sci USA*. 2012;109:5523–8.
  19. Nie Q, Wang C, Song G, Ma H, Kong D, Zhang X, et al. Mitofusin 2 deficiency leads to oxidative stress that contributes to insulin resistance in rat skeletal muscle cells. *Mol Biol Rep*. 2014;41:6975–83.
  20. de Brito OM, Scorrano L. Mitofusin 2 tethers endoplasmic reticulum to mitochondria. *Nature*. 2008;456:605–10.
  21. Liesa M, Borda-d'Agua B, Medina-Gomez G, Lelliott CJ, Paz JC, Rojo M, et al. Mitochondrial fusion is increased by the nuclear coactivator PGC-1beta. *PLoS ONE*. 2008;3:e3613.
  22. Zorzano A. Regulation of mitofusin-2 expression in skeletal muscle. *Appl Physiol Nutr Metab*. 2009;34:433–9.
  23. Li J, Liu X, Wang H, Zhang W, Chan DC, Shi Y. Lysocardiolipin acyltransferase 1 (ALCAT1) controls mitochondrial DNA fidelity and biogenesis through modulation of MFN2 expression. *Proc Natl Acad Sci USA*. 2012;109:6975–80.
  24. Lu Z, Li SJ, Zhao SX, Fa XN. Upregulated miR-17 regulates hypoxia-mediated human pulmonary artery smooth muscle cell proliferation and apoptosis by targeting mitofusin 2. *Med Sci Monit*. 2016;22:3301–8.
  25. Huang S, Chen Z, Wu W, Wang M, Wang R, Cui J, et al. MicroRNA-31 promotes arterial smooth muscle cell proliferation and migration by targeting mitofusin-2 in arteriosclerosis obliterans of the lower extremities. *Exp Ther Med*. 2018;15:633–40.
  26. Zhang Y, Yang L, Gao YF, Fan ZM, Cai XY, Liu MY, et al. MicroRNA-106b induces mitochondrial dysfunction and insulin resistance in C2C12 myotubes by targeting mitofusin-2. *Mol Cell Endocrinol*. 2013;381:230–40.
  27. Zhang Y, He W, Gao YF, Fan ZM, Gao CL, Xia ZK. MicroRNA-106b regulates skeletal muscle insulin sensitivity and glucose homeostasis by targeting mitofusin-2. *Mol Med Rep*. 2017;16:6858–63.
  28. Pan L, Zhou L, Yin W, Bai J, Liu R. miR-125a induces apoptosis, metabolism disorder and migration impairment in pancreatic cancer cells by targeting Mfn2-related mitochondrial fission. *Int J Oncol*. 2018;53:124–36.
  29. Zhang R, Zhou HM, Jiang L, Mao YR, Cui XM, Xie B, et al. MiR-195 dependent roles of mitofusin2 in the mitochondrial dysfunction of hippocampal neurons in SAMP8 mice. *Brain Res*. 2016;1652:135–43.
  30. Zhang R, Garrett Q, Zhou HM, Wu XX, Mao YR, Cui XM, et al. Upregulation of miR-195 accelerates oxidative stress-induced retinal endothelial cell injury by targeting mitofusin 2 in diabetic rats. *Mol Cell Endocrinol*. 2017;452:33–43.
  31. Sun M, Yu HY, Zhang YY, Li ZJ, Gao W. MicroRNA-214 mediates isoproterenol-induced proliferation and collagen synthesis in cardiac fibroblasts. *Sci Rep*. 2015;5:18351.
  32. Wu J, Li J, Chen WK, Liu S, Liu JH, Zhang JS, et al. MicroRNA-214 affects fibroblast differentiation of adipose-derived mesenchymal stem cells by targeting mitofusin-2 during pelvic floor dysfunction in SD rats with birth trauma. *Cell Physiol Biochem*. 2017;42:1870–87.
  33. Bucha S, Mukhopadhyay D, Bhattacharyya NP. Regulation of mitochondrial morphology and cell cycle by microRNA-214 targeting Mitofusin2. *Biochem Biophys Res Commun*. 2015;465:797–802.
  34. Qin L, Yang W, Wang YX, Wang ZJ, Li CC, Li M, et al. MicroRNA-497 promotes proliferation and inhibits apoptosis of cardiomyocytes through the downregulation of Mfn2 in a mouse model of myocardial ischemia-reperfusion injury. *Biomed Pharmacother*. 2018;105:103–14.
  35. Zhou X, Zhang L, Zheng B, Yan Y, Zhang Y, Xie H, et al. MicroRNA-761 is upregulated in hepatocellular carcinoma and regulates tumorigenesis by targeting Mitofusin-2. *Cancer Sci*. 2016;107:424–32.
  36. Lv L, Li T, Li X, Xu C, Liu Q, Jiang H, et al. The lncRNA Plscr4 controls cardiac hypertrophy by regulating miR-214. *Mol Ther Nucleic Acids*. 2018;10:387–97.
  37. Leboucher GP, Tsai YC, Yang M, Shaw KC, Zhou M, Veenstra TD, et al. Stress-induced phosphorylation and proteasomal degradation of mitofusin 2 facilitates mitochondrial fragmentation and apoptosis. *Mol Cell*. 2012;47:547–57.
  38. Kumar S, Pan CC, Shah N, Wheeler SE, Hoyt KR, Hempel N, et al. Activation of mitofusin2 by Smad2-RIN1 complex during mitochondrial fusion. *Mol Cell*. 2016;62:520–31.
  39. Hinman MN, Lou H. Diverse molecular functions of Hu proteins. *Cell Mol Life Sci*. 2008;65:3168–81.
  40. Ratti A, Fallini C, Colombrita C, Pascale A, Laforenza U, Quattrone A, et al. Post-transcriptional regulation of neuro-oncological ventral antigen 1 by the neuronal RNA-binding proteins ELAV. *J Biol Chem*. 2008;283:7531–41.
  41. Abdelmohsen K, Hutchison ER, Lee EK, Kuwano Y, Kim MM, Masuda K, et al. miR-375 inhibits differentiation of neurites by lowering HuD levels. *Mol Cell Biol*. 2010;30:4197–210.
  42. Lee EK, Kim W, Tominaga K, Martindale JL, Yang X, Subaran SS, et al. RNA-binding protein HuD controls insulin translation. *Mol Cell*. 2012;45:826–35.
  43. Kim C, Kim W, Lee H, Ji E, Choe YJ, Martindale JL, et al. The RNA-binding protein HuD regulates autophagosome formation in pancreatic beta cells by promoting autophagy-related gene 5 expression. *J Biol Chem*. 2014;289:112–21.
  44. Kim C, Lee H, Kang H, Shin JJ, Tak H, Kim W, et al. RNA-binding protein HuD reduces triglyceride production in pancreatic beta cells by enhancing the expression of insulin-induced gene 1. *Biochim Biophys Acta*. 2016;1859:675–85.
  45. Kim C, Jeong DE, Heo S, Ji E, Rho JG, Jung M, et al. Reduced expression of the RNA-binding protein HuD in pancreatic neuroendocrine tumors correlates with low p27(Kip1) levels and poor prognosis. *J Pathol*. 2018;246:231–43.
  46. Lu H, Koshkin V, Allister EM, Gyulkhanyan AV, Wheeler MB. Molecular and metabolic evidence for mitochondrial defects associated with beta-cell dysfunction in a mouse model of type 2 diabetes. *Diabetes*. 2010;59:448–59.
  47. Mulder H, Ling C. Mitochondrial dysfunction in pancreatic beta-cells in Type 2 diabetes. *Mol Cell Endocrinol*. 2009;297:34–40.
  48. Supale S, Li N, Brun T, Maechler P. Mitochondrial dysfunction in pancreatic beta cells. *Trends Endocrin Metab*. 2012;23:477–87.
  49. Allen M, Bird C, Feng W, Liu G, Li W, Perrone-Bizzozero NI, et al. HuD promotes BDNF expression in brain neurons via selective stabilization of the BDNF long 3'UTR mRNA. *PLoS ONE*. 2013;8:e55718.
  50. Kang MJ, Abdelmohsen K, Hutchison ER, Mitchell SJ, Grammatikakis I, Guo R, et al. HuD regulates coding and non-coding RNA to induce APP- $\rightarrow$ A $\beta$  processing. *Cell Rep*. 2014;7:1401–9.
  51. Chen H, Detmer SA, Ewald AJ, Griffin EE, Fraser SE, Chan DC. Mitofusins Mfn1 and Mfn2 coordinately regulate mitochondrial fusion and are essential for embryonic development. *J Cell Biol*. 2003;160:189–200.

52. Franco A, Kitsis RN, Fleischer JA, Gavathiotis E, Kornfeld OS, Gong G, et al. Correcting mitochondrial fusion by manipulating mitofusin conformations. *Nature*. 2016;540:74–9.
53. Wollheim CB, Maechler P. beta-cell mitochondria and insulin secretion—messenger role of nucleotides and metabolites. *Diabetes*. 2002;51:S37–42.
54. Mulder H. Transcribing beta-cell mitochondria in health and disease. *Mol Metab*. 2017;6:1040–51.
55. Bhansali S, Bhansali A, Walia R, Saikia UN, Dhawan V. Alterations in mitochondrial oxidative stress and mitophagy in subjects with prediabetes and Type 2 diabetes mellitus. *Front Endocrinol*. 2017;8:347.
56. Kanter M, Akpolat M, Aktas C. Protective effects of the volatile oil of *Nigella sativa* seeds on beta-cell damage in streptozotocin-induced diabetic rats: a light and electron microscopic study. *J Mol Histol*. 2009;40:379–85.
57. Barbosa de Queiroz K, Honorato-Sampaio K, Rossoni Junior JV, Andrade Leal D, Pinto AB, Kappes-Becker L, et al. Physical activity prevents alterations in mitochondrial ultrastructure and glucometabolic parameters in a high-sugar diet model. *PLoS ONE*. 2017;12:e0172103.
58. Zhang Z, Wakabayashi N, Wakabayashi J, Tamura Y, Song WJ, Sereda S, et al. The dynamin-related GTPase Opa1 is required for glucose-stimulated ATP production in pancreatic beta cells. *Mol Biol Cell*. 2011;22:2235–45.
59. Schultz J, Waterstradt R, Kantowski T, Rickmann A, Reinhardt F, Sharoyko V, et al. Precise expression of Fis1 is important for glucose responsiveness of beta cells. *J Endocrinol*. 2016;230:81–91.
60. Pascale A, Amadio M, Scapagnini G, Lanni C, Racchi M, Provenzani A, et al. Neuronal ELAV proteins enhance mRNA stability by a PKCalpha-dependent pathway. *Proc Natl Acad Sci USA*. 2005;102:12065–70.
61. Fujiwara T, Mori Y, Chu DL, Koyama Y, Miyata S, Tanaka H, et al. CARM1 regulates proliferation of PC12 cells by methylating HuD. *Mol Cell Biol*. 2006;26:2273–85.
62. Poy MN, Hausser J, Trajkovski M, Braun M, Collins S, Rorsman P, et al. miR-375 maintains normal pancreatic alpha- and beta-cell mass. *Proc Natl Acad Sci USA*. 2009;106:5813–8.
63. Ferrick DA, Neilson A, Beeson C. Advances in measuring cellular bioenergetics using extracellular flux. *Drug Discov Today*. 2008;13:268–74.